An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?

Overview of attention for article published in Nature Biotechnology, January 2019

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 20 X posts from 14 X users, with an upper bound of 346,382 followers.

RT @WNicholsonPrice: EU's new proposed IP exception for generic/biosimilar exports: a good thing, a disaster, some sort of mix? @TiMinCeBI…

RT @WNicholsonPrice: EU's new proposed IP exception for generic/biosimilar exports: a good thing, a disaster, some sort of mix? @TiMinCeBI…

RT @WNicholsonPrice: EU's new proposed IP exception for generic/biosimilar exports: a good thing, a disaster, some sort of mix? @TiMinCeBI…

EU's new proposed IP exception for generic/biosimilar exports: a good thing, a disaster, some sort of mix? @TiMinCeBIL @ #BiosimilarInnovation (here's the paper w/ @akesselheim & Jonathan Darrow; @CeBIL_Center, @PORTAL_Research: https://t.co/VZhcfME2i

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 16 additional X posts.